HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.

Abstract
Fractalkine (FKN) is a unique CX3C chemokine (CX3CL1) known to induce both adhesion and migration of leukocytes mediated by a membrane-bound and a soluble form, respectively. Its function is mediated through CX3C receptor (CX3CR), which is expressed by T(H)1 immune cells including T cells and natural killer (NK) cells. FKN was shown to be expressed in >90% of 68 neuroblastoma samples as determined by cDNA microarray analysis. Here, we characterized the effect of FKN in the neuroblastoma microenvironment using a syngeneic model genetically engineered to secrete FKN. We show FKN-mediated migration, adhesion, and IFN-gamma secretion of immune effector cells, but limited antineuroblastoma activity, in vitro and in vivo. Therefore, we tested the hypothesis that a combined increase of FKN and interleukin-2 (IL-2) in the neuroblastoma microenvironment induces an effective antitumor immune response. For this purpose, IL-2 was targeted to ganglioside GD2, which is highly expressed on neuroblastoma tissue, using an anti-GD2 antibody IL-2 immunocytokine (ch14.18-IL-2). Only mice bearing FKN- and IL-2-enriched neuroblastoma tumors exhibited a reduction in primary tumor growth and a complete eradication of experimental liver metastases. The depletion of T cells and NK cells in vivo abrogated the effect, and these effector cells showed the highest cytolytic activity in vitro. Finally, only the FKN- and IL-2-enriched neuroblastoma microenvironment resulted in T-cell activation and the release of proinflammatory cytokines. In summary, we showed for the first time the immunologic mechanisms by which targeted IL-2 treatment of neuroblastoma with an FKN-rich microenvironment induces an effective antitumor response.
AuthorsYan Zeng, Nicole Huebener, Stefan Fest, Silke Weixler, Ulrike Schroeder, Gerhard Gaedicke, Rong Xiang, Alexander Schramm, Angelika Eggert, Ralph A Reisfeld, Holger N Lode
JournalCancer research (Cancer Res) Vol. 67 Issue 5 Pg. 2331-8 (Mar 01 2007) ISSN: 0008-5472 [Print] United States
PMID17332365 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CX3CL1 protein, human
  • Chemokine CX3CL1
  • Chemokines, CX3C
  • Cx3cl1 protein, mouse
  • Interleukin-2
  • Membrane Proteins
Topics
  • Animals
  • Cell Line, Tumor
  • Chemokine CX3CL1
  • Chemokines, CX3C (genetics, metabolism, physiology)
  • Female
  • Gene Targeting
  • Humans
  • Immunity, Cellular
  • Immunotherapy (methods)
  • Interleukin-2 (genetics, therapeutic use)
  • Killer Cells, Natural (immunology)
  • Membrane Proteins (genetics, metabolism, physiology)
  • Mice
  • Mice, Inbred Strains
  • Neoplasm Metastasis
  • Neoplasm Transplantation
  • Neuroblastoma (immunology, metabolism, pathology, therapy)
  • T-Lymphocytes (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: